PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 28836422
OWN - NLM
STAT- MEDLINE
DA  - 20170824
DCOM- 20170825
LR  - 20170828
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 377
IP  - 8
DP  - 2017 Aug 24
TI  - Adjuvant Capecitabine for Breast Cancer.
PG  - 790-1
LID - 10.1056/NEJMc1708487 [doi]
FAU - Ruades Ninfea, Jose I
AU  - Ruades Ninfea JI
AD  - University of Vermont Medical Center, Burlington, VT [email protected]
FAU - Burdette-Radoux, Susan
AU  - Burdette-Radoux S
AD  - Maimonides Medical Center, Brooklyn, NY
FAU - Wood, Marie E
AU  - Wood ME
AD  - University of Vermont Medical Center, Burlington, VT
LA  - eng
PT  - Letter
PT  - Comment
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Adjuvants, Immunologic)
RN  - 6804DJ8Z9U (Capecitabine)
SB  - AIM
SB  - IM
CON - N Engl J Med. 2017 Jun 1;376(22):2147-2159. PMID: 28564564
CIN - N Engl J Med. 2017 Aug 24;377(8):791-2. PMID: 28834474
MH  - Adjuvants, Immunologic
MH  - *Breast Neoplasms
MH  - *Capecitabine
MH  - Humans
EDAT- 2017/08/25 06:00
MHDA- 2017/08/26 06:00
CRDT- 2017/08/25 06:00
AID - 10.1056/NEJMc1708487 [doi]
AID - 10.1056/NEJMc1708487#SA1 [pii]
PST - ppublish
SO  - N Engl J Med. 2017 Aug 24;377(8):790-1. doi: 10.1056/NEJMc1708487.